Thomas Jefferson University

Jefferson Digital Commons
College of Pharmacy Faculty Papers

Jefferson College of Pharmacy

11-20-2017

Natural Bioactive Compounds: Alternative Approach to the
Treatment of Glioblastoma Multiforme
Vilas Desai
Thomas Jefferson University

Alok Bhushan
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/pharmacyfp
Part of the Medical Pharmacology Commons, and the Pharmacy and Pharmaceutical Sciences
Commons

Let us know how access to this document benefits you
Recommended Citation
Desai, Vilas and Bhushan, Alok, "Natural Bioactive Compounds: Alternative Approach to the
Treatment of Glioblastoma Multiforme" (2017). College of Pharmacy Faculty Papers. Paper 32.
https://jdc.jefferson.edu/pharmacyfp/32
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in College of Pharmacy Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Hindawi
BioMed Research International
Volume 2017, Article ID 9363040, 10 pages
https://doi.org/10.1155/2017/9363040

Review Article
Natural Bioactive Compounds: Alternative Approach to
the Treatment of Glioblastoma Multiforme
Vilas Desai and Alok Bhushan
Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
Correspondence should be addressed to Alok Bhushan; alok.bhushan@jefferson.edu
Received 6 June 2017; Accepted 17 October 2017; Published 20 November 2017
Academic Editor: Marta M. Alonso
Copyright © 2017 Vilas Desai and Alok Bhushan. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Glioblastoma multiforme (GBM) is the most frequent, primary malignant brain tumor prevalent in humans. GBM characteristically
exhibits aggressive cell proliferation and rapid invasion of normal brain tissue resulting in poor patient prognosis. The current
standard of care of surgical resection followed by radiotherapy and chemotherapy with temozolomide is not very effective. The
inefficacy of the chemotherapeutic agents may be attributed to the challenges in drug delivery to the tumor. Several epidemiological
studies have demonstrated the chemopreventive role of natural, dietary compounds in the development and progression of cancer.
Many of these studies have reported the potential of using natural compounds in combination with chemotherapy and radiotherapy
as a novel approach for the effective treatment of cancer. In this paper, we review the role of several natural compounds individually
and in combination with chemotherapeutic agents in the treatment of GBM. We also assess the potential of drug delivery approaches
such as the Gliadel wafers and role of nanomaterial based drug delivery systems for the effective treatment of GBM.

1. Introduction
Human gliomas constitute the major form of primary brain
tumors [1, 2]. These tumors can be classified as low-grade
gliomas, glioblastomas, or anaplastic astrocytomas, based
on the degree of invasiveness and pathology of the tumor
[2, 3]. The most malignant form of astrocytoma is called
glioblastoma multiforme (GBM), typically characterized by
an increased angiogenesis, invasion of normal brain tissues,
and necrosis, and has the worst prognosis [4–6]. At a cellular
level, GBM is poorly differentiated, with round or pleomorphic cells that are multinucleated and anaplastic [6–8].
Depending on origin, it is categorized as either primary GBM,
which arises de novo from the glial cells, or secondary GBM,
which arises from preexisting lower grade astrocytoma [6, 9].
The hallmark feature of primary GBM is overexpression of
the EGFR gene and loss of heterozygosity of PTEN while secondary GBM exhibits loss of p53 and overexpression of PGDF
[8–10]. Although the causes of GBM are relatively unclear, its
risk may be increased by certain factors (i.e., family history,
brain trauma, and immune system alteration) and conditions
(i.e., Li-Fraumeni’s syndrome) [5, 6]. The current therapy
includes surgical resection of the tumor, radiotherapy, and
adjuvant chemotherapy with temozolomide [3, 9, 11]. The

complete surgical resection of gliomas is difficult, and due
to local invasion and infiltration of normal tissue the tumor
recurs leading to death of patients with glioblastoma [3, 9].
The efficacy of chemotherapy is further decreased by the
presence of the blood brain barrier that limits the delivery of
chemotherapeutics to the brain [9, 11]. The current therapy
minimally improves the median survival time of patients
from 12 months to ∼14.6 months. The 5-year survival rate of
treated patients is <10% [1, 3, 9]. Hence, there is an imperative
need for the development of novel, targeted, and effective
therapies for GBM.

2. Natural Compounds in Cancer
Conventional cancer therapies such as chemotherapy and
radiotherapy essentially exert their cytotoxic effects by damaging the DNA of cancer cells [12, 13]. However, limitations
exist with these treatments when used as single modalities
due to the high heterogeneity in solid tumors and the
deregulation of several cell signaling cascades [14–18]. GBM
is particularly difficult to treat because of the heterogeneity
of the tumor, its highly aggressive infiltration into the surrounding tissues, and the presence of blood brain barrier [3,
4]. Multimodality treatment approaches can be an effective

2
strategy for GBM wherein different therapies or therapeutic
agents with distinct molecular mechanisms are combined to
exert an improved cytotoxic effect on cancer cells [10, 11].
In particular, multimodal therapy can work effectively by
sensitizing cancer cell DNA by one agent to the damaging
effects of the other [12, 13, 19].
In recent years, several epidemiological studies have
investigated the role of natural, dietary compounds in
influencing the development, progression, and metastasis of
cancer [19–22]. A wide range of natural compounds have
been recognized for their antioxidant nature and for their
cancer chemopreventive potential, including soy isoflavones,
curcumin, epigallocatechin, resveratrol, and retinoids [23–
25]. The main objective of this review paper is to discuss the
role of these natural compounds in enhancing the efficacy of
chemotherapeutic drugs in GBM treatment as reported by a
number of studies. We also review the significance of novel
drug delivery methods such as the Gliadel wafers and the
emerging role of nanomedicine in drug delivery for GBM
treatment.
2.1. Isoflavones in Glioma. Several studies have demonstrated the benefits of consumption of a plant-based diet
of fruits and vegetables [13–19]. Soy isoflavones, such as
genistein, daidzein, and biochanin A, are natural polyphenolic compounds with potent antioxidant, anti-inflammatory,
and weak estrogenic properties [18, 19]. Isoflavones are
usually derived from soy and soy-based products but are
also found in chick peas, nuts, grain products, and red
clover [12, 15]. They have been implicated in cancer prevention, based on the epidemiological reports that South
Asian populations have heavy consumption of soy and soycontaining foods and low incidence of cancer and cardiovascular diseases compared to the people in Western
civilizations [14, 19]. Furthermore, they also reportedly have
beneficial effects in endocrine-responsive cancer, osteoporosis, menopause, and coronary heart diseases [21, 22]. Interest in soy isoflavones has been renewed by the research
showing the estrogen-like ring in their structure, indicating
that they may be a better alternative to synthetic selective
estrogen receptor modulators (SERMs) currently used in
breast cancer prevention and hormone replacement therapy
[20, 21, 23].
The intestinal microflora in the body converts isoflavones
to isoflavonoids which reportedly play a critical, preventive role in mutation and promotional phases of cancer
progression [21, 22]. Cancer chemopreventive properties of
isoflavones in improving the efficacy of chemotherapy and
radiotherapy have been demonstrated in vitro and in vivo,
and a number of clinical trials are focusing on the antiinvasive and antiangiogenic properties of these compounds
for treatment of GBM [18, 21, 23].
2.1.1. Genistein. Genistein is one type of soy isoflavone
that has shown promise as a chemopreventive agent due
to its antioxidant and anti-inflammatory properties and its
ability to potently inhibit angiogenesis and metastasis [16,
18, 20]. Our previous studies have reported its ability to
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inhibit invasion in a coculture model of GBM by inhibiting tyrosine kinase EGFR [24]. Other studies have shown
that genistein prevents the hypermethylation of promoter
regions of tumor suppressor genes (i.e., p21, BRCA1) by
inhibiting DNA methyltransferases in different cancer types
[20, 22]. In other research, genistein inhibited the expression
of apurinic/apyrimidinic (AP) endonuclease 1 (APE1) in
prostate cancer cells in a dose dependent manner [18, 23].
APE1 is an enzyme involved in the DNA base excision
repair (BER) and redox signaling, and elevated levels have
been correlated to resistance to chemotherapy [13, 15, 16].
Genistein is also a known inhibitor of protein tyrosine kinase
(PTK), and it competes with ATP to bind to the tyrosine
kinase domain thereby inhibiting the activation of tyrosine
kinase-mediated downstream signaling processes [20, 22,
24]. A recent study on genistein showed its inhibitory effects
on telomerase activity and subsequent cell cycle arrest in
radiosensitive brain tumor cells [15, 17, 22]. There have
been several clinical studies at phases I, II, and III on
genistein as an adjuvant compound on patients undergoing
chemotherapy or radiotherapy for prostate, bladder, or breast
cancer [25]. In a study on 20 prostate cancer patients treated
with pure genistein, it was observed that there were no
genotoxic effects or any change in micronuclei number and
no damage to the chromosomes compared to the nontreated
lot [26]. A wide range of clinical studies on isoflavones have
demonstrated a good safety profile even at maximal dose
which is encouraging for the population [26]. However, in
clinical studies, various factors such as the stage or type of
cancer and differences in the metabolic state of individuals
play a critical role in determining the outcome of such studies.
Nonetheless, the results of a number of studies on isoflavones
in cancer are encouraging and hold a potential for further
research.
2.1.2. Biochanin A. Biochanin A, a bioactive isoflavone and
a prodrug or methoxy form of genistein that is found in
red clover, has been shown to inhibit the incidence and
growth of LNCaP xenograft tumors in athymic mice [21, 23].
Earlier studies showed that it has chemopreventive and anticancer potential against glioblastoma, breast cancer, prostate
cancer, and oral cancer cells [11, 17, 23, 24]. Biochanin A
is documented to be less mutagenic than genistein, and
hence it may be a more suitable candidate for use as a
chemopreventive agent [14, 18]. It is rapidly degraded to
genistein, genistein conjugates, and biochanin A conjugates,
which confer anticancer properties to the compound [20, 23].
It has tyrosine kinase inhibitory properties that are weaker
than those of genistein and inhibits the growth of breast,
colon, and prostate cancer cells in vitro [11, 17, 18, 27]. Studies
have also shown that biochanin A has inhibitory potential
on the development of lung tumors induced in mice by
benzo(a)pyrene [23].
Both biochanin A and genistein have been found to
inhibit both serum and EGF-stimulated growth of human
prostate cancer cells [17, 18]. Our earlier studies showed that
genistein and biochanin A inhibit the invasion of glioblastoma cells by inhibiting matrix metalloproteases (MMPs)
[11]. Both isoflavones have also been found to enhance
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the efficacy of rapamycin in inhibiting the mTOR pathway
in glioblastoma cells and their rapamycin-induced feedback
upregulation of AKT [24].
2.2. Resveratrol. Resveratrol (trans-3,4 ,5-trihydroxystilbene)
(RSV) is a naturally occurring polyphenolic phytoalexin
present in grapes, mulberries, peanuts, and vegetables [27,
28]. It has attracted substantial attention in recent years due to
its antioxidant and anti-inflammatory properties, which give
it efficacy in treating cardiovascular diseases, and due to its
neuroprotective effects in penetrating the blood brain barrier,
which give it efficacy for treating ischemia and hypoxia [29].
The chemopreventive and antioncogenic effects of RSV have
been reported in several cancer types [27–29]. Researchers
found that RSV prevented the development of skin cancer in mice during the different stages of carcinogenesis
[27] and inhibited DMBA-induced mammary carcinogenesis
[28]. Clinical trial studies in patients with colorectal cancer
have shown that RSV hinders tumor cell proliferation and
increases caspase-3 in the malignant hepatic tissue compared
to the placebo patients [30, 31]. In a phase I trial study in
healthy volunteers, it was observed that ingesting RSV (0.5
to 5 g/day for 29 days) led to a decrease in systemic IGF-1 and
IGFBP-3 levels, which may contribute to the antiproliferative
activity of RSV [32].
In earlier studies by Gangemi et al., RSV was found to
induce apoptosis by activating caspase-3 in a human glioma
cell line U251 [33]. Further, Ryu et al. demonstrated that RSV
reduced the invasion in U373MG glioma cells induced via
TNF-𝛼, by regulating the NF-𝜅B activation and expression of
upa/upar [34]. A study by Jang et al. reported the chemopreventive and anticarcinogenic effects of RSV in the different
stages of carcinogenesis, namely, initiation, promotion, and
progression [28]. RSV causes cell death in GBM cells through
mechanisms such as autophagy, apoptosis, and senescence
[28, 35]. It exerts its cytotoxic and cytostatic effects in cancer
cells by modulating the cell cycle at specific points including
an S phase arrest in medulloblastoma cells [35].
A study by Filippi-Chiela et al. on several GBM cell
lines found that RSV potentiates the toxicity of TMZ in
combination treatment mainly by inhibiting TMZ-induced
G2/M arrest followed by induction of senescence and MC
[35]. This G2/M arrest was p53 independent, as it was
observed in all glioma cells tested, including p53 mutant cells
U251 and U138 [35]. Cilibrasi et al. investigated the effects
of RSV on seven glioma stem cell (GSC) lines derived from
GBM patients. They observed that RSV inhibited the cell
proliferation, increased cell mortality, and reduced motility
of the cells by modulating the Wnt signaling pathway [36–
38]. These findings clearly suggest that RSV possesses potent
therapeutic properties and may work as effective adjuvant
molecules in combination therapy of cancer.
2.3. Epigallocatechin Gallate. Epigallocatechin gallate
(EGCG) is a major polyphenolic green tea component and
a major catechin in green tea [39, 40]. EGCG has been
extensively investigated for its potential chemopreventive
and chemosensitizing properties in a variety of malignant
cancers [41, 42]. It has the ability to bind to GRP78, a key
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prosurvival component of ER stress response system, and
inactivate its antiapoptotic function, an interaction that
makes cancer cells more chemosensitive [41]. A number of
studies have shown that EGCG increases the sensitivity of
different cancer types to different apoptotic drugs, such as
5-fluorouracil, gemcitabine, or taxol, in vitro [42–44] and to
doxorubicin and paclitaxel in vivo [44, 45]. Studies have also
reported that EGCG can reverse drug resistance by inducing
apoptosis and inhibiting P-gp expression and ABCG2 in
drug-resistant cancer cells of the ovaries, breast, and lung
[40, 42]. There have been reports of the inhibition of Wnt
signaling by EGCG in breast cancer cells and an upregulation
of p53 transcriptional activity in LNCaP cells [42, 46, 47]. In
a double-blind placebo-controlled clinical trials with green
tea catechins (GTCs) against prostate cancer, it was shown
that GTCs were safe and effective in treating premalignant
lesions before the prostate cancer developed [48]. In another
phase II study among 42 patients of androgen independent
prostate carcinoma, a minimal antineoplastic activity with a
decline in prostate specific antigen (PSA) levels was reported
[49]. However, there have been a few positive reports with
EGCG inducing apoptosis in leukemic B-cells in majority of
patients of chronic lymphocytic leukemia (CLL) and patients
with low-grade B-cell malignancies [50].
A recent study by Zhang et al. reported that EGCG
reduced U87 and C6 GSLC (Glioma Stem-Like Cells) viability, neurosphere formation capability, and migration. EGCG
also sensitized GSLCs to temozolomide, a phenomenon
associated with downregulation of P-gp in vitro [40, 43].
EGCG was observed to induce apoptosis in U87 GSLCs
by reducing Akt phosphorylation, inactivating antiapoptotic
protein Bcl-2, upregulating the apoptosis-promoting protein
Bax, and cleaving PARP [51, 52]. Since gliomas are sensitive
to apoptosis through the downregulation of Bcl-2 family
[47, 51], EGCG is potentially an effective molecule to target
GSLCs associated with inhibition of an Akt-related pathway [52]. Although it remains unclear whether EGCG can
achieve chemosensitization of cancer cells across the blood
brain barrier, which would be required for the treatment
of malignant gliomas, these studies provided clear evidence
that polyphenol compounds like EGCG can significantly
augment the chemotherapeutic efficacy of cancer drugs in a
combination treatment both in vitro and in vivo.
2.4. Retinoids. Retinoids have also been found to potentially
enhance the efficacy of chemotherapy and radiotherapy in
GBM. Retinoids are a class of chemical compounds that are
related to vitamin A and are fat soluble [53, 54]. Retinol is
transported from the liver to the target tissues as retinolbinding protein and is then enzymatically converted to
retinaldehyde and consequently to retinoic acid [53, 55].
The retinoid signaling pathways play an important role in
neurogenesis, dendritic growth of hippocampal neurons, and
higher cognitive functions [53, 54]. Studies have shown that
retinoids strongly inhibit the cell proliferation and migration
in primary cultures of human glioblastoma multiforme [54,
55]. Retinoids can successfully induce differentiation but
cannot induce apoptosis. However a synthetic analog of alltrans retinoic acid (ATRA), N-(4-hydroxyphenyl) retinamide
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(4-HPR), exhibits both antiproliferative and proapoptotic
effects [55]. 4-HPR is a much more effective and relatively less
toxic compound than ATRA, and it is proven to be effective
even in ATRA-resistant cells [55, 56].
In one notable study in which 4-HPR treatment was
used in combination with the knockdown of survivin, a
prosurvival protein overexpressed in GBM that has been
positively correlated with GBM cell proliferation, around 80%
of the cells were apoptotic and in vivo angiogenesis studies
showed a noticeable decrease in tumor vascularization [54,
56, 57]. In a similar study, when GBM cells were treated
with retinoids, differentiation of astrocytes was induced and
telomerase activity was inhibited, allowing for an increased
sensitivity to interferon-𝛾 therapy [58]. Moreover, treatments
with retinoids have been shown to reduce levels of inflammatory factors, potentially making the GBM cells sensitive to
radiotherapy [53, 54].
2.5. Other Notable Natural Compounds with
Promising Anticancer Activity against GBM
2.5.1. Cannabis and Cannabinoids. Cannabis sativa L. and
its derivative compounds cannabinoids have been reported
to have a broad range of pharmacological effects mediated
specifically by two plasma membrane receptors (CB1 and
CB2) [59–62]. Δ9 -Tetrahydrocannabinol (THC) is the most
potent and abundant endocannabinoid in cannabis that
can bind to and activate specific cell receptors [60, 63].
Several studies have reported the efficacy of cannabinoids
in the treatment of pain, inflammation, depression, neurological disorders, and cancer [59, 60, 62–66]. The anticancer
potential of cannabinoids against gliomas may be mediated
through the CB1 receptor which is densely expressed in
the brain as a seven-transmembrane domain G proteincoupled receptor and is activated by the receptor agonist Δ9 THC in vitro and in vivo in the treatment of glioblastoma
(GBM) [61–66]. The activation of CB1 and CB2 by Δ9 THC impairs cancer cell proliferation and invasion, induces
apoptosis by ceramide accumulation in culture, and also
reduces the tumor volume in animals [59, 63]. Δ9 -THC in
combination with temozolomide (TMZ) has shown a robust
anticancer activity in TMZ-sensitive as well as TMZ-resistant
tumors in glioma xenografts [65]. A phase I clinical study
in brain tumor patients has reported the safety of direct
intratumoral injection of tetrahydrocannabinol in recurring
GBM [66]. However, to validate the efficacy of cannabis
in preventing gliomas and the methods of administering
the other derivatives of cannabis safely, more clinical trials
are needed [66]. In recognition of the promising anticancer
potential of Δ9 -THC in the preclinical studies with a fair
safety profile, it has become an important therapeutic target
for the treatment of GBM and has also prompted a human
clinical trial [61, 66].
2.5.2. Neurostatin. Neurostatin is a natural glycosphingolipid, an O-acetylated ganglioside GD1b, present in the
mammalian brain, and shows strong inhibition of astroblast
and astrocytoma division [66, 67]. Although it exhibits a
high inhibitory activity against gliomas, it is relatively less
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abundant in the brain [68, 69]. However, neurostatin has
now been extensively purified from the ganglioside extracts
of rats and bovine and porcine brain and is observed to
be cytostatic against C6 glioma cells and grade III and IV
human astrocytoma cells [66, 69]. In particular neurostatin
has been shown to impair glioma cell proliferation in vivo
by inducing cell cycle arrest and potentiating the immune
cell response to the tumor through the activation of CD4+
and CD8+ lymphocytes [67]. Valle-Argos et al. reported
that the anticancer activity of neurostatin in vitro and
in vivo in gliomas is mediated through the arrest of cell
cycle progression, while interfering with the angiogenic and
invasive mechanisms [66, 67]. Neurostatin was shown to
inhibit the expression of cell cycle promoters (cyclins) and
CDKs while upregulating cell cycle inhibitors such as p21
and p27 [67, 70]. The promitogenic pathways of MAPK and
PI3K were also reportedly blocked through the inhibition
of EGFR signaling [67, 70]. Gangliosides like neurostatin
are ubiquitous molecules with potent and specific biological
actions, and the preclinical studies strongly indicate that it is a
promising therapeutic candidate in the treatment of gliomas
[69, 70].
2.5.3. Bipolaris setariae Fungi. Bipolaris is a genus of dematiaceous hyphomycetes with more than 100 species [71].
Ophiobolin A (OP-A), a sesterterpenoid that is produced
by the plant pathogenic fungi, was purified from the culture extract of Drechslera gigantea and characterized to be
an effective phytotoxin [72, 73]. Further studies on the
compound showed a broad spectrum of biological and
pharmacological characteristics including anticancer activity
[72, 73]. A number of studies have reported the anticancer
activity of OP-A with an IC50 in micromolar concentration
range against different glioblastoma and neuroblastoma cells
[73, 74]. A study by Bury et al. reported that OP-A caused
marked changes in the organization of the actin cytoskeleton
and induced paraptosis through the disruption of internal
potassium ion homeostasis in glioblastoma cells [73]. The
reported studies indicate that the OP-A causes mitochondrial
dysfunction and ER stress, impairs cell cycle progression, and
inhibits multiple oncogenic signaling pathways in glioblastoma cells [73, 74]. Table 1 shows some of the natural
compounds used in the treatment of GBM and their reported
mechanism of action in in vitro and in vivo studies. OP-A thus
represents a class of natural compounds that can be used to
combat cancer types exhibiting different levels of resistance
to proapoptotic stimuli [72, 74].

3. New Approaches to Drug Delivery
3.1. Gliadel Wafers. Despite surgical resection of GBM tumor
followed by radiotherapy and chemotherapy (i.e., carmustine
(BCNU) and temozolomide), recurrences are inevitable [75,
76]. Effective delivery of drugs to the tumor is a major
challenge due to systemic toxicities and the need for transport
across the blood brain barrier [75–77]. Gliadel wafers offer a
novel system for delivering chemotherapeutic agents to GBM
cells. Approved for treating recurrent glioblastoma by FDA
in 1995, Gliadel wafers are biodegradable polymers loaded
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Table 1: Natural compounds and their mechanism of action in GBM and other cancer cells.
Natural
compounds
Isoflavones
(biochanin A,
genistein, etc.)
Resveratrol
Epigallocatechin
A (EGCG)
Retinoids
Cannabis
Neurostatin
Bipolaris
setariae fungi

Target mechanisms
Inhibits MMPs and thus invasion & metastasis.
Inhibits tyrosine kinase mediated downstream signaling.
Induces apoptosis by activating caspase-3.
Modulates cell cycle at specific points.
Binds to GRP78 (prosurvival component of ER stress response system) and inactivates its antiapoptotic
function. Inhibits P-gp expression thus reversing drug resistance in cancer cells.
Reduces levels of inflammatory factors making cancer cells sensitive to radiotherapy. Increases sensitivity to
specific therapies such as interferon-𝛾 therapy by inhibiting telomerase activity.
Induces apoptosis by sustained accumulation of ceramide that also upregulates the ERK activity.
Causes ER stress and inhibition of pAkt/mTOR leading to autophagy-mediated cell death.
Inhibits cell cycle progression (suppresses cyclins and CDKs and promotes inhibitors such as p21 & p27).
Impairs promitogenic pathways of MAPK and PI3K by blocking EGFR signaling.
Disrupts the potassium ion homeostasis causing mitochondrial dysfunction and ER stress. Impairs cell cycle
progression.

with carmustine [77, 78]. They are implanted at the resection
site, and the drug is gradually released over a period of 2-3
weeks as the wafer polymer degrades [78–80]. In a placebocontrolled, double-blind phase 3 trial in 2003, 2-year survival
was higher among glioblastoma patients treated with Gliadel
wafers (15.8%) than patients who received placebo (8.3%);
median survival was 13.8 months in the patients treated with
the Gliadel wafer and 11.6 months in the placebo group [79–
81].
Another study treated glioma patients who had undergone surgery with Gliadel wafers soaked with temozolomide [80, 81]. The patients treated with Gliadel wafer and
temozolomide survived 20.7 months (median) and the 2year survival rate was 36% [80]. Several other studies have
reported that when Gliadel wafers are implanted in the
resection cavity of malignant gliomas, local drug delivery is
improved and systemic side effects are reduced in recurrent
glioma treatment. However, there have also been reports that
use of Gliadel wafers resulted in adverse effects, including
cerebral edema, surgical site infection, perioperative seizures,
and severe hydrocephalus leading to death [77–79, 82].
Hence, the practice of using Gliadel wafers for the treatment
of GBM needs to be reevaluated.
3.2. Nanomedicine and Drug Delivery across the Blood Brain
Barrier. During the last couple of decades, nanomedicine
has progressed significantly, especially in the field of cancer
therapeutics. A key feature of the nanomaterials is their size
which operate at the same scale as the biological molecules
and pathways. This means that nanoscale materials can be
designed to interact with biological entities in a direct,
efficient, and precise manner and that they can help us understand biological processes and pathways at the molecular
level [83, 84]. Nanometerials can be designed to circumvent
or cross the BBB and hence may serve as an effective drug
delivery system in GBM treatment.
Treatment for GBM is often impaired because therapeutic
agents cannot be delivered adequately to the target tumor

cells; the problem is further compromised by the presence
of blood brain barrier (BBB) [85, 86]. Blood brain barrier
(BBB) is a unique anatomical structure mainly formed by
tight junctions and adherence junctions between the brain
endothelial cells that selectively regulate the flow of ions,
nutrients, and cells into the brain [85, 87]. This restricted
permeation of drugs to the GBM cells, allowing a fraction of
cells called cancer stem cells (CSCs) to evade drug cytotoxicity and develop therapeutic resistance [86, 88, 89]. Further,
the poor delivery of chemotherapeutic agents can also be
attributed to their large size, hydrophobic nature, and their
efflux by the MDR efflux pumps expressed by BBB and tumor
cells [87, 88]. Thus, targeted, effective, therapeutic regimens
are needed that can cross the BBB and reach their target in
the brain [90, 91]. A few proposed strategies include passive
permeation of lipidated drugs, development of prodrugs that
can hijack the transport mechanism of BBB, and drug-loaded
nanocarriers [87, 88, 92, 93].
Apart from a limited number of liposoluble, small
molecules, most of the other molecules need a specific
transport system to cross the BBB [84, 92]. Hence, a more
selective and targeted approach such as the nanoparticles
based system can be employed to design targeted therapies.
Colloidal systems such as the nanoparticle system allow
for the design of nanocarriers with surface properties to
overcome the biochemical/biophysical barriers, and can be
tailored to deliver the drugs across the BBB. Moreover,
the surface properties of the nanocarriers can be modified
for a selective, controlled drug release with minimal side
effects and increased efficacy [84, 94, 95]. Nanomaterial based
chemotherapeutic agents such as the liposomes, dendrimers,
or polymeric micelles are reported to circumvent the BBB
and reach the target site of action [87, 88, 96, 97]. Several
nanomaterials-based drugs have been evaluated for the treatment of GBM and other cancers. Table 2 features some of
these drugs which have been approved by the regulatory
authority and are in clinical use for GBM as well as other types
of cancers [85–100].

Liposomal cisplatin
Liposomal Irinotecan (e.g., CPX 1)
Polymeric NPs conjugated with camptothecin or
bevacizumab
Lipid encapsulated daunorubicin

Temozolomide (TMZ)
Carmustine (BCNU)

Cisplatin

Irinotecan

CRLX101

DaunoXome

Gold nanoparticles

No
No

Antimitotic by DNA intercalation and inhibits
topoisomerase II

Yes

No

Yes
No

No

No

Permeability
to BBB
No
No

Antiangiogenic inhibitor of HIF-1

DNA alkylating agent
DNA alkylating agent
Inorganic Pt2+ complexes DNA alkylating and
intercalating agent
Inhibits DNA topoisomerase I & induces single strand
DNA lesions

DNA damage by ROS, mitochondrial dysfunction.
Directs immune cells to tumor

DNA damage by ROS, peroxidation

CNTs, nanographene oxide
Au NPs (spheres, rods, and shells), Au NPs modified
with TNF-𝛼, TGF-𝛽, or thio-PEG.
Au NPs conjugated to T cells
TMZ bound to nanocarriers (e.g., cucurbit[n]uril)
BCNU bound nanocomplex

Inhibits nucleic acid synthesis, ROS
Microtubule stabilizing

PEGylated liposome/doxorubicin hydrochloride
Nanoparticle albumin-bound paclitaxel

Doxil
Abraxane
Carbon nanomaterials (carbon nanotubes (CNTs),
graphene oxide)

Characteristics

Nanocarrier

Name

Table 2: Nanomaterial-based drugs in clinical use for the treatment of GBM.
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Glioblastomas exhibit a high degree of heterogeneity and
the integrity of BBB varies, with high-grade gliomas showing
a leaky BBB and low-grade gliomas showing an intact BBB
[98–100]. Hence, the GBM therapies need to be designed
to identify disease-related changes in the BBB and to tailor
the drug or drug nanocarriers accordingly [99, 100]. Ideally,
the carrier agents should be cationic for optimal vascular
absorption, small, stable in biological fluids, and tailored to
carry a large drug payload [97, 99, 100]. The physiological
and pathophysiological status of the gliomas also needs to be
considered for optimization of any chemotherapeutic agent
for GBM.

4. Conclusions and Future Directions
The current standard therapy of GBM has shown little
promise and there have been efforts to design novel, targeted,
effective therapeutics. Moreover, the current chemotherapy
may also be a cause of drug resistance in GBM treatment as
it severely destabilizes the cell metabolism and cell signaling
network. Here we have reviewed a number of studies that
report the role of various natural, dietary compounds that
show significant improvement in the efficacy of chemotherapeutics in combination therapy of GBM both in vitro and
in vivo. Glioblastoma is a highly heterogeneous and often
fatal cancer, and attacking its chemoresistance is a critical
step in combating its growth. Several of the studies reviewed
emphasize the relative nontoxicity of the natural compounds
and improvement in efficacy of combination therapy at a
lower dosage level. We have also reviewed the role of Gliadel
wafers after surgery in the local delivery of drugs such as
BCNU and temozolomide in brain tumor treatments. The
main challenge of GBM treatment is the inadequacy of drug
delivery due to the presence of BBB. We have discussed the
role of nanocarriers and nanomedicine in overcoming the
obstacle of BBB to improve the efficacy of drug delivery
and thus the GBM treatment. The studies reviewed above
clearly demonstrate the anticancer potential of these natural
compounds and indicate that they can be an alternative
approach to a more effective and relatively nontoxic GBM
treatment.

Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this paper.

References
[1] J. L. Villano, T. E. Seery, and L. R. Bressler, “Temozolomide
in malignant gliomas: current use and future targets,” Cancer
Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 647–655,
2009.
[2] A. V. Knizhnik, W. P. Roos, T. Nikolova et al., “Survival and
death strategies in glioma cells: autophagy, senescence and
apoptosis triggered by a single type of temozolomide-induced
DNA damage,” PLoS ONE, vol. 8, no. 1, Article ID e55665, pp.
1–12, 2013.

7
[3] J. Zhang, M. F. G. Stevens, and T. D. Bradshaw, “Temozolomide:
mechanisms of action, repair and resistance,” Current Molecular
Pharmacology, vol. 5, no. 1, pp. 102–114, 2012.
[4] C. J. Sandberg, G. Altschuler, J. Jeong et al., “Comparison of
glioma stem cells to neural stem cells from the adult human
brain identifies dysregulated Wnt- signaling and a fingerprint
associated with clinical outcome,” Experimental Cell Research,
vol. 319, no. 14, pp. 2230–2243, 2013.
[5] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of
human brain tumour initiating cells,” Nature, vol. 432, no. 7015,
pp. 396–401, 2004.
[6] T. Aoki, N. Hashimoto, and M. Matsutani, “Management of
glioblastoma,” Expert Opinion on Pharmacotherapy, vol. 8, no.
18, pp. 3133–3146, 2007.
[7] J. M. Gallego, J. A. Barcia, and C. Barcia-Mariño, “Fatal outcome
related to carmustine implants in glioblastoma multiforme,”
Acta Neurochirurgica, vol. 149, no. 3, pp. 261–265, 2007.
[8] K. K. Jain, “Use of nanoparticles for drug delivery in glioblastoma multiforme,” Expert Review of Neurotherapeutics, vol. 7,
no. 4, pp. 363–372, 2007.
[9] M. C. Chamberlain, “Temozolomide: therapeutic limitations in
the treatment of adult high-grade gliomas,” Expert Review of
Neurotherapeutics, vol. 10, no. 10, pp. 1537–1544, 2010.
[10] S. Vinogradov and X. Wei, “Cancer stem cells and drug
resistance: the potential of nanomedicine,” Nanomedicine, vol.
7, no. 4, pp. 597–615, 2012.
[11] S. Puli, J. C. K. Lai, and A. Bhushan, “Inhibition of matrix
degrading enzymes and invasion in human glioblastoma
(U87MG) cells by isoflavones,” Journal of Neuro-Oncology, vol.
79, no. 2, pp. 135–142, 2006.
[12] A. R. M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin,
“Perspectives for cancer prevention with natural compounds,”
Journal of Clinical Oncology, vol. 27, no. 16, pp. 2712–2725, 2009.
[13] N. P. Gullett, A. R. M. Ruhul Amin, S. Bayraktar et al., “Cancer
prevention with natural compounds,” Seminars in Oncology, vol.
37, no. 3, pp. 258–281, 2010.
[14] H. Adlercreutz and W. Mazur, “Phyto-oestrogens and Western
diseases,” Annals of Medicine, vol. 29, no. 2, pp. 95–120, 1997.
[15] G. G. Hillman and V. Singh-Gupta, “Soy isoflavones sensitize
cancer cells to radiotherapy,” Free Radical Biology & Medicine,
vol. 51, no. 2, pp. 289–298, 2011.
[16] F. H. Sarkar and Y. Li, “Using chemopreventive agents to
enhance the efficacy of cancer therapy,” Cancer Research, vol.
66, no. 7, pp. 3347–3350, 2006.
[17] I. U. Ahmad, J. D. Forman, F. H. Sarkar et al., “Soy isoflavones
in conjunction with radiation therapy in patients with prostate
cancer,” Nutrition and Cancer, vol. 62, no. 7, pp. 996–1000, 2010.
[18] J. J. Raffoul, F. H. Sarkar, and G. G. Hillman, “Radiosensitization
of prostate cancer by soy isoflavones,” Current Cancer Drug
Targets, vol. 7, no. 8, pp. 759–765, 2007.
[19] A. Bapat, M. L. Fishel, and M. R. Kelley, “Going ape as
an approach to cancer therapeutics,” Antioxidants & Redox
Signaling, vol. 11, no. 3, pp. 651–667, 2009.
[20] F. H. Sarkar, Y. Li, Z. Wang, and D. Kong, “Cellular signaling
perturbation by natural products,” Cellular Signalling, vol. 21,
no. 11, pp. 1541–1547, 2009.
[21] M. Goodman, R. M. Bostick, O. Kucuk, and D. P. Jones, “Clinical
trials of antioxidants as cancer prevention agents: past, present,
and future,” Free Radical Biology & Medicine, vol. 51, no. 5, pp.
1068–1084, 2011.

8
[22] S. Banerjee, Y. Li, Z. Wang, and F. H. Sarkar, “Multi-targeted
therapy of cancer by genistein,” Cancer Letters, vol. 269, no. 2,
pp. 226–242, 2008.
[23] V. Singh-Gupta, M. C. Joiner, L. Runyan et al., “Soy isoflavones
augment radiation effect by inhibiting APE1/ref-1 DNA repair
activity in non-small cell lung cancer,” Journal of Thoracic
Oncology, vol. 6, no. 4, pp. 688–698, 2011.
[24] S. Puli, A. Jain, J. C. K. Lai, and A. Bhushan, “Effect of
combination treatment of rapamycin and isoflavones on mtor
pathway in human glioblastoma (U87) cells,” Neurochemical
Research, vol. 35, no. 7, pp. 986–993, 2010.
[25] M. K. Virk-Baker, T. R. Nagy, and S. Barnes, “Role of phytoestrogens in cancer therapy,” Planta Medica, vol. 76, no. 11, pp.
1132–1142, 2010.
[26] W. Miltyk, C. N. Craciunescu, L. Fischer et al., “Lack of
significant genotoxicity of purified soy isoflavones (genistein,
daidzein, and glycitein) in 20 patients with prostate cancer.,”
American Journal of Clinical Nutrition, vol. 77, no. 4, pp. 875–
882, 2003.
[27] V. Sehdev, C. K. J. Lai, and A. Bhushan, “Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling
Pathways in HER-2-Positive Breast Cancer Cells,” Journal of
Oncology, vol. 2009, pp. 1–10, 2009.
[28] M. Jang, L. Cai, G. O. Udeani et al., “Cancer chemopreventive
activity of resveratrol, a natural product derived from grapes,”
Science, vol. 275, no. 5297, pp. 218–220, 1997.
[29] C. Gill, S. E. Walsh, C. Morrissey, J. M. Fitzpatrick, and R. W. G.
Watson, “Resveratrol sensitizes androgen independent prostate
cancer cells to death-receptor mediated apoptosis through
multiple mechanisms,” The Prostate, vol. 67, no. 15, pp. 1641–
1653, 2007.
[30] K. R. Patel, V. A. Brown, D. J. L. Jones et al., “Clinical
pharmacology of resveratrol and its metabolites in colorectal
cancer patients,” Cancer Research, vol. 70, no. 19, pp. 7392–7399,
2010.
[31] L. M. Howells, D. P. Berry, P. J. Elliott et al., “Phase I randomized,
double-blind pilot study of micronized resveratrol (SRT501)
in patients with hepatic metastases—safety, pharmacokinetics,
and pharmacodynamics,” Cancer Prevention Research, vol. 4, no.
9, pp. 1419–1425, 2011.
[32] V. A. Brown, K. R. Patel, M. Viskaduraki et al., “Repeat
dose study of the cancer chemopreventive agent resveratrol in
healthy volunteers: safety, pharmacokinetics, and effect on the
insulin-like growth factor axis,” Cancer Research, vol. 70, no. 22,
pp. 9003–9011, 2010.
[33] R. M. R. Gangemi, F. Griffero, D. Marubbi et al., “SOX2
silencing in glioblastoma tumor-initiating cells causes stop of
proliferation and loss of tumorigenicity,” Stem Cells, vol. 27, no.
1, pp. 40–48, 2009.
[34] J. Ryu, B. M. Ku, Y. K. Lee et al., “Resveratrol reduces tnf-alphainduced u373mg human glioma cell invasion through regulating nf-kappab activation and upa/upar expression,” Anticancer
Research, vol. 31, pp. 4223–4230, 2011.
[35] E. C. Filippi-Chiela, M. P. Thomé, M. M. Bueno e Silva
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